{"transactions":[{"id":2615,"issuer":{"id":1907,"kind":"organization","name":"Veradermics, Inc","symbol":"MANE"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:35:03.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":19300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service."}],"balance_after":19300,"derivative":{"exercise_price":97.51,"expiration_date":"2036-09-01","underlying":"Common Stock","underlying_shares":19300},"source":{"system":"sec-edgar","filing":"0001628280-26-060491","document":"wk-form4_1788467701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026060491/wk-form4_1788467701.xml","form_type":"4"}},{"id":2614,"issuer":{"id":1907,"kind":"organization","name":"Veradermics, Inc","symbol":"MANE"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:35:03.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service."}],"balance_after":9650,"source":{"system":"sec-edgar","filing":"0001628280-26-060491","document":"wk-form4_1788467701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026060491/wk-form4_1788467701.xml","form_type":"4"}},{"id":739356,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:15:38.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027."}],"balance_after":25000,"derivative":{"exercise_price":2.63,"exercise_date":"2027-06-10","expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001793796-26-000002","document":"wk-form4_1781295336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000179379626000002/wk-form4_1781295336.xml","form_type":"4"}},{"id":1182820,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-03T00:15:08.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.93,"exercise_date":"2026-04-01","expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001372514-25-000028","document":"wk-form4_1743639302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000028/wk-form4_1743639302.xml","form_type":"4"}},{"id":1280281,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Global Therapeutics Lead"}}],"security":"Common Stock","published_at":"2025-02-06T15:58:01.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95212,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015359","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015359/ownership.xml","form_type":"4"}},{"id":1280280,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Global Therapeutics Lead"}}],"security":"Common Stock","published_at":"2025-02-06T15:58:01.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":9733,"price":3.65,"value":35525.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":95212,"source":{"system":"sec-edgar","filing":"0000950170-25-015359","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015359/ownership.xml","form_type":"4"}},{"id":1359020,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Global Therapeutics Lead"}}],"security":"Common Stock","published_at":"2024-11-19T16:31:35.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":3908,"price":4.17,"value":16296.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted\nstock units granted on October 17, 2022 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover\nagreement that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary\ntrade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to\nprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the\nnumber of shares sold at each separate price."}],"balance_after":104945,"source":{"system":"sec-edgar","filing":"0001479290-24-000130","document":"wk-form4_1732051887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000130/wk-form4_1732051887.xml","form_type":"4"}},{"id":1459508,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-03T19:15:26.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025."}],"balance_after":1778,"derivative":{"exercise_price":4.35,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0001372514-24-000089","document":"wk-form4_1720034119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000089/wk-form4_1720034119.xml","form_type":"4"}},{"id":1766712,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-10-03T20:44:38.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024."}],"balance_after":5000,"derivative":{"exercise_price":0.5677,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001372514-23-000144","document":"wk-form4_1696365864.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000144/wk-form4_1696365864.xml","form_type":"4"}},{"id":1965225,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-08T01:13:47.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024."}],"balance_after":8000,"derivative":{"exercise_price":3.83,"expiration_date":"2033-03-03","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001372514-23-000030","document":"wf-form4_167823801678609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000030/wf-form4_167823801678609.xml","form_type":"4"}},{"id":2407996,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2022-02-08T20:40:33.000Z","date":"2022-02-04","kind":"tax_withholding","acquired":false,"shares":927,"price":7.05,"value":6535.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock."}],"balance_after":30749,"source":{"system":"sec-edgar","filing":"0001209191-22-007902","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919122007902/doc4.xml","form_type":"4"}},{"id":2413136,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-04T00:02:55.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023."}],"balance_after":5000,"derivative":{"exercise_price":0.77,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-22-011492","document":"tm225348d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922011492/tm225348d3_4.xml","form_type":"4"}},{"id":2413135,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-04T00:02:55.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years."}],"balance_after":4000,"derivative":{"exercise_price":0.77,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-22-011492","document":"tm225348d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922011492/tm225348d3_4.xml","form_type":"4"}},{"id":2512466,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2021-11-15T16:44:11.000Z","date":"2021-11-11","kind":"tax_withholding","acquired":false,"shares":2162,"price":12.06,"value":26073.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock."}],"balance_after":31676,"source":{"system":"sec-edgar","filing":"0001209191-21-064473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919121064473/doc4.xml","form_type":"4"}},{"id":2874223,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-02-08T18:07:32.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first 48 monthly anniversaries of February 4, 2021."}],"balance_after":50000,"derivative":{"exercise_price":17.64,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-008586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919121008586/doc4.xml","form_type":"4"}},{"id":2874222,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2021-02-08T18:07:32.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of Common Stock are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first four anniversaries of February 4, 2021."}],"balance_after":33838,"source":{"system":"sec-edgar","filing":"0001209191-21-008586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919121008586/doc4.xml","form_type":"4"}},{"id":2982906,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2020-11-12T17:05:00.000Z","date":"2020-11-11","kind":"tax_withholding","acquired":false,"shares":2162,"price":13.05,"value":28214.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock."}],"balance_after":22838,"source":{"system":"sec-edgar","filing":"0001209191-20-058030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919120058030/doc4.xml","form_type":"4"}},{"id":3372638,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-13T16:08:06.000Z","date":"2019-11-11","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted under the Plan and is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, as to 25% of the underlying shares on November 11, 2020 and as to the remaining underlying shares in substantially equal installments on each of the first 36 monthly anniversaries of November 11, 2020."}],"balance_after":110000,"derivative":{"exercise_price":19.05,"expiration_date":"2029-11-11","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-19-056323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919119056323/doc4.xml","form_type":"4"}},{"id":3372637,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":1908,"kind":"person","name":"Hollander David","position":1,"cik":"0001793796","reported_name":"Hollander David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2019-11-13T16:08:06.000Z","date":"2019-11-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of Common Stock were granted under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan (the \"Plan\") and are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first four anniversaries of November 11, 2019."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-19-056323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1337553/000120919119056323/doc4.xml","form_type":"4"}}]}